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Background: Smoking in asthma occurs frequently and is associated with increased symptom
severity, an impaired response to corticosteroids, and accelerated lung function decline.
Airway pathology in smoking asthmatics is characterized by neutrophilia and epithelial changes
such as goblet cell hyperplasia and increased proliferation. Bronchial CD8þ T cells are impli-
cated in lung function decline in asthma and COPD. We hypothesized that smoking modifies
airway inflammation in asthma by increasing the number of CD8þ T cells at an early stage.
Objectives & methods: To study effects of smoking on airway pathology in bronchial biopsies
from atopic patients with controlled intermittent or mild persistent asthma (12 smokers, 9.7
py and 11 never-smokers, 0.0 py; 20e50 yrs; FEV1 > 70% predicted; PC20MCh < 8 mg/mL, no
ICS) using immunohistochemistry.
Results: Smoking asthmatics showed higher numbers of bronchial CD8þ T cells (55.8 vs 23.9
cells/0.1 mm2; p Z 0.001) and CD68þ macrophages (7.5 vs 4.6 cells/0.1 mm2, p Z 0.012),
and a lower CD4þ/CD8þ cell ratio (0.16 vs 0.40; p Z 0.007) compared with non-smoking asth-
matics, but no difference in neutrophils. Furthermore, the % intact epithelium was higher in
smoking asthmatics (49.3 vs 23.3, p Z 0.001).
Conclusion: Smoking asthmatics with a limited smoking history show a distinct pattern of
airway pathology characterized by a bronchial infiltrate of CD8þ T cells and CD68þof Pulmonary Rehabilitation, Rijnlands Rehabilitation Center, P.O. Box 176, 2300 AD Leiden, The
x: þ31 71 5195153.
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960 A.J. Ravensberg et al.macrophages, and epithelial remodelling resembling COPD-like features. This raises the hy-
pothesis that early presence of CD8þ T cells contributes to disease progression in smoking asth-
matics.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Smoking occurs frequently in patients with asthma. Recent
surveys on smoking prevalence report 21e26% current
smokers in populations of patients with asthma.1,2 Detri-
mental effects of active smoking in asthma include worse
asthma control,3,4 an impaired response to corticoste-
roids5,6 and accelerated lung function decline.7e9
The mechanisms by which cigarette smoking contrib-
utes to disease severity in asthma are incompletely un-
derstood, but it has been suggested that cigarette smoking
may change inflammation and airway remodelling in
asthma to become more similar to that in COPD.10 Ciga-
rette smoking by itself is associated with airway inflam-
mation and features of airway remodelling including
increased epithelial proliferation,11 squamous cell meta-
plasia,12 goblet cell hyperplasia, smooth muscle hyper-
trophy, and increases in bronchial glands mass.13,14 In
asthma, airway inflammation and airway remodelling are
thought to cause impairment in lung function. Allergic
inflammation in asthma is characterized by increased
numbers of CD4þ T cells, eosinophils and mast cells, and
has been associated with changes in airway epithelium
such as increased mucin production. Furthermore, CD8þ T
lymphocytes have been implicated in lung function decline
in asthma.15 Smokers with chronic obstructive pulmonary
disease (COPD) show a distinct cellular infiltrate charac-
terized by CD8þ T lymphocytes which has been suggested
to be related to airflow limitation.16,17 It could be postu-
lated that these cells play a role in the observed pro-
gressive lung function decline in smoking asthmatics. Thus
far, it has been reported that smoking asthmatics show
neutrophilia and increased expression and production of
IL-8 in sputum samples and bronchial biopsies, whereas
eosinophilia is less prominent compared with non-smoking
asthmatics.18e21 Furthermore, epithelial changes such as
goblet cell hyperplasia, squamous cell metaplasia and
higher proliferation rate have been reported.19,21 To date,
the influence of smoking on CD8þ T lymphocyte infiltration
in the bronchial mucosa of smoking asthmatics has not
been studied. In view of potential development of an
overlap syndrome between asthma and COPD,22 the in-
fluence of smoking on inflammation in asthma per se
should preferably be examined at early stages of smoking
history.
We hypothesized that smoking modifies airway pathol-
ogy in asthma at an early stage resulting in an inflammatory
cellular infiltrate in the bronchial mucosa characterized by
increased numbers of CD8þ T cells. To this end we analysed
bronchial biopsies from steroid-naı¨ve non-smoking and
smoking patients with intermittent and mild persistent
asthma. Smokers with asthma were characterized by a
limited smoking history and duration.Methods
Subjects and study design
Two groups of patients with intermittent and mild persistent
asthma23 were included in this cross-sectional study. Bron-
chial biopsy samples, lung function measurements and
clinical data from twelve asthmatics who were never-
smokers were available from a previous investigation.24
Twelve smoking asthmatics were newly recruited during an
overlapping time period. At screening, medical history was
taken and lung function,25 airway hyperresponsiveness26 and
allergy to 10 common air-borne allergens27 were deter-
mined. During the second visit reversibility was determined
and a bronchoscopy was performed to obtain bronchial bi-
opsies. Tominimize variation in laboratory readings between
the two groups, identical and standardized study procedures
were used which were performed by the same laboratory
technicians.
Lung function expressed as forced expiratory volume in
1 s (FEV1) was >70% predicted post-bronchodilator.
25 All
patients were hyperresponsive to methacholine (provoca-
tive concentration causing a 20% fall of FEV1 (PC20) < 8 mg/
ml)26 and atopic. They were well-controlled with bron-
chodilators only, and had not used oral or inhaled cortico-
steroids 3 months prior to and during the study. Smoking
asthmatics were current smokers with 7.5e25 py. The
institutional review board for human studies approved the
protocol and subjects gave written informed consent.Bronchoscopy, immunohistochemistry and image
analysis
Smokers were requested to refrain from smoking  1 h
before bronchoscopy was performed according to a stan-
dardized protocol.28 Three biopsies were taken at (sub)
segmental level, fixed in formaldehyde and embedded in
paraffin. For both groups haematoxylin-eosin stained sec-
tions were used to select the two morphological best bi-
opsies per patient for analysis.29 The observer was blinded
with regard to the patient’s number and clinical status
during selection, processing and analysis of the biopsy
samples.
Immunohistochemistry was performed simultaneously
for both groups on newly cut sections using mouse mono-
clonal antibodies directed against CD3, CD4, CD8 (T lym-
phocytes), neutrophil elastase (NE), CD68 (macrophages),
EG2 (eosinophils) and AA1 (mast cells) to identify the
number of inflammatory cells per 0.1 mm2 using digital
analysis in a 125 mm deep zone beneath the basement
membrane (BM) from which glands and airway smooth
muscle were excluded. All cell counts were performed
Smoking and asthma pathology 961twice by an experienced observer. Intraclass correlation
coefficients showed high consistency between repeated
measurements (range: 0.996e0.999).
Mucin producing cells were identified using Periodic
acid-Schiff/Alcian blue (PAS/AB) and densitometry analysis
to determine the percentage of positively stained intact
epithelium. For evaluation of the epithelium the length of
the BM was traced of all intact non-squamous metaplastic
epithelium, intact squamous metaplastic epithelium, and
damaged epithelium.30 To determine epithelial prolifera-
tion the number of Ki67 positively stained cells was counted
in intact epithelium (numbers per length of BM).
Statistical analysis
Data are reported as mean values and standard deviations
(SD) or median with interquartile range (IQR). Between-
group differences were analysed by 2-tailed unpaired t-
tests for patient characteristics and ManneWhitney tests
for data from biopsy samples. Spearman’s rank correlation
coefficients were determined to explore associations be-
tween functional parameters and data from bronchial bi-
opsies. P values < 0.05 were considered to indicate
statistical significance.
Results
Patient characteristics
After evaluation of the bronchial biopsies, one patient from
the group of non-smoking asthmatics was excluded from
analysis because of haemorrhagic biopsy samples. The
characteristics of the 11 non-smoking and 12 smoking pa-
tients with intermittent and mild persistent asthma are
given in Table 1. Smoking asthmatics were current smokers
with a median smoking duration of 11 years and 9.7 pack-
years. They were slightly older than the non-smoking
asthmatics (median age 27 vs 22 years respectively;
p < 0.05). There were no significant differences between
the groups with respect to asthma duration, lung function,
reversibility or airway hyperresponsiveness. All patientsTable 1 Patient characteristics.
Non
N 11
Gender [M/F] 4/7
Age [years] 22 (
FEV1 post [%predicted] 103.
FEV1/FVC post 0.86
PC20 [mg/ml] 1.13
Reversibility FEV1 [%] 8.8
Asthma duration [years] 14.1
Atopy [nr of atopic patients] 11
Smoking history [pack-years] 0.0
Smoking duration [years] 0.0
Cigarette consumption [cigarettes/day] 0.0
PC20 methacholine is represented as geometric mean (SD in doubling d
a p < 0.05 smoking vs non-smoking asthmatics.were atopic to one or more of 10 common air-borne
allergens.
Bronchial inflammation
Smoking asthmatics had significantly more CD8þ T lym-
phocytes (Figs. 1 and 2) and CD68þ macrophages, and less
eosinophils in the bronchial mucosa compared with non-
smoking asthmatics (Fig. 2). The ratio of CD4þ/CD8þ T
cells was significantly lower in smoking asthmatics. There
were no differences between groups in the numbers of
CD3þ and CD4þ T lymphocytes, mast cells and neutrophils
(Table 2). The median area of lamina propria analysed was
0.32 (0.18e0.52) mm2.
Features of airway epithelium
Smoking asthmatics showed a significantly higher percent-
age of intact epithelium compared with non-smoking
asthmatics [52.0 (37.2e67.3) vs [23.3 (18.3e33.7);
p Z 0.001] (Fig. 3), whereas the percentage of PAS/ABþ
area [12.0 (5.2e18.2) vs 5.8 (4.0e12.7), respectively] and
the number of Ki67þ proliferating cells [9.2 (4.4e24.7) vs
5.1 (0.83e12.5), respectively] did not differ between
groups. The median analysed BM length per biopsy was 2.1
(1.1e4.8) mm. Squamous cell metaplasia was observed in
two smoking asthmatics but not in non-smoking asthmatics
(Fig. 4).
Relation between smoking, lung function,
bronchial inflammation and features of airway
epithelium
In smoking asthmatics no significant correlations were
found between smoking duration or pack-years, and lung
function (FEV1 % predicted or FEV1/FVC) pre or post
bronchodilator.
The numbers of inflammatory cells in the lamina propria
were not significantly associated with pack-years or smok-
ing duration in smoking asthmatics. There was only a trend
towards a significant relation between the number of pack--smoking asthmatics Smoking asthmatics
12
4/8
21e24) 27 (24e40)a
9  10.8 98.0  11.3
 0.07 0.80  0.10
 1.48 1.91  1.76
 3.9 8.2  5.1
 7.7 18.6  10.0
12
(0.0e0.0) 9.7 (8.3e17.0)a
(0.0e0.0) 11.0 (10.3e25.8)a
(0.0e0.0) 14 (11e18)a
ose). Other data are represented as mean  SD or median (IQR).
Figure 1 CD8þ T lymphocyte infiltration observed in bron-
chial biopsies obtained from a non-smoking [A] and smoking [B]
asthmatic patient. Original magnification: 200.
962 A.J. Ravensberg et al.years and CD68þ macrophages (rZ 0.57; pZ 0.053) in this
group. When smoking and non-smoking asthmatics were
analysed together, pack-years and smoking duration were
significantly associated with the number of CD68þ macro-
phages (r Z 0.57; p Z 0.004 and r Z 0.57; p Z 0.008,
respectively) and CD8þ T cells (rZ 0.61; pZ 0.002 for both
parameters), whereas inverse relationships with the ratio
of CD4þ/CD8þ T cells were also found (r Z 0.43;
p Z 0.043 and r Z 0.44; p Z 0.035, respectively). In
smoking asthmatics, lung function was not related to the
number of CD8þ T cells.
Pack-years and smoking duration were not significantly
associated with features of airway epithelium. When both
groups were analysed together the numbers of CD68þ
macrophages and CD8þ T cells and CD4þ/CD8þ cell ratio
were significantly associated with the percentage of intact
epithelium (rZ 0.47; pZ 0.023, rZ 0.60; pZ 0.003, and
r Z 0.47; p Z 0.023, respectively).
Discussion
This study evaluated the effects of smoking on bronchial
inflammation and airway epithelium in steroid-naı¨ve pa-
tients with mild intermittent and persistent asthma.
Smokers with asthma with a limited smoking history show a
distinct pattern of bronchial inflammation characterized byhigher numbers of CD8þ T lymphocytes and CD68þ macro-
phages and lower numbers of eosinophils whereas the
airway epithelium showed less damage compared with
never-smokers with asthma. These features represent early
smoking-induced airway pathology and may contribute to
disease progression in asthma.
In line with our hypothesis, we demonstrated that
increased numbers of CD8þ T lymphocytes and a decreased
CD4þ/CD8þ T cell ratio characterize the cellular infiltrate in
the lamina propria in smokers with asthma compared to
never-smokers with asthma. Increased numbers of CD8þ T
lymphocytes are also found in peripheral and central air-
ways of smokers with COPD compared to smokers without
airflow limitation. An association between CD8þ T lym-
phocytes and lung function has been described in a com-
bined group of smokers with and without airflow
limitation.16,17,31 Our patients had relatively few pack-
years which could explain the fact that we did not
observe such a relation. It could be argued that the number
of subjects included in our study was limited. However, a
sample size of 10 patients per group was estimated to
detect a two-fold difference in CD8þ T cells with a power of
90%, and indeed we found a significant difference. Since
the focus of the current study was to determine whether
smoking induces changes in airway pathology in asthma, we
did not include healthy subjects. Therefore, we cannot
answer the question whether asthma is a prerequisite for
smoking-induced bronchial infiltration by CD8þ T lympho-
cytes in our group of patients. Studies comparing bronchial
biopsies obtained from smokers with normal lung function
and never-smokers showed no difference in the number of
CD8þ T lymphocytes.16,17,31,32 However, these groups were
not comparable with our cohort of patients with respect to
age and smoking history. Thus, we can only speculate that
existing lung pathology is required for increased CD8þ T cell
infiltration in the bronchial mucosa.
What mechanisms cause CD8þ T lymphocytes to accu-
mulate in the lung and what could be the consequence?
First of all, endogenous stimuli such as modified self-
antigens induced by xenobiotic compounds and/or free
radicals in cigarette smoke could contribute to recruitment
of these cells. Also exogenous factors that elicit an immune
response could be involved such as viruses. Smokers have a
higher frequency of viral infections than non-smokers.33,34
Asthma patients who smoke show reduced numbers of
CD83þ mature dendritic cells and B lymphocytes compared
with never-smokers with asthma35 and therefore may be
more prone to develop lower respiratory tract infections.
Viral infections can induce antigen-specific CD8þ T lym-
phocytes persisting in the lungs for many months.36
Persistence and activation of CD8þ lymphocytes could
contribute to airway and remodelling thereby adding to the
development of airflow impairment.37 In fact, lower respi-
ratory tract infections in smokers with mild COPD and ex-
acerbations in asthma have been associated with decline in
lung function.38,39 Moreover, CD8þ T lymphocytes have
been shown to be related to the annual decline in FEV1 in
patients with asthma.15 Our findings and the fact that
smoking has been associated with an accelerated decline in
lung function in asthma7e9 may suggest that CD8þ T lym-
phocytes could have a significant role in the smoking-
induced airway pathology and clinical course of asthma.
Figure 2 CD8þ T cells [A], ratio of CD4þ/CD8þ T cells [B], CD68þ cells [C], and EG2þ cells [D] in bronchial mucosa from non-
smoking and smoking asthmatics (NSA and SA respectively). Cell counts are expressed as numbers of cells per 0.1 mm2; medians
are depicted as a horizontal line.
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also characterized by higher numbers of CD68þ macro-
phages and lower numbers of eosinophils compared with
non-smokers, whereas the number of neutrophils did not
differ between groups. Reduced eosinophilia in smokers
with asthma has been reported previously in both
sputum5,20 and bronchial tissue,21 but has not beenTable 2 Bronchial inflammation in non-smoking and
smoking patients with asthma.
Non-smoking
asthmatics
Smoking
asthmatics
P
value
CD3þ cells 61.0 (35.0e89.1) 55.3 (50.9e70.9) 0.951
CD4þ cells 12.4 (5.9e18.7) 8.9 (4.7e13.4) 0.176
CD8þ cells 23.9 (20.7e33.6) 55.8 (36.4e72.0) 0.001
Ratio CD4þ/CD8þ
cells
0.40 (0.32e0.88) 0.16 (0.09e0.32) 0.007
CD68þ cells 4.6 (1.5e7.2) 7.5 (6.1e10.4) 0.012
NEþ cells 2.1 (0.6e2.8) 2.3 (0.3e3.8) 0.854
EG2þ cells 2.1 (1.2e8.6) 0.7 (0.5e1.6) 0.012
AA1þ cells 12.7 (9.9e16.5) 6.6 (1.9e13.9) 0.124
Numbers of cells are expressed as median (IQR) per 0.1 mm2
lamina propria.confirmed in all studies investigating effects of smoking on
bronchial inflammation in asthma.18,19 We found no signif-
icant difference in bronchial neutrophilia between groups,
whereas others have reported higher numbers ofFigure 3 Percentage intact epithelium in bronchial biopsies
obtained from non-smoking (NSA) and smoking (SA) asthmatic
patients. Medians are depicted as a horizontal line.
Figure 4 Squamous cell metaplasia in a bronchial biopsy
obtained from a smoking asthmatic patient. Original magnifi-
cation: 200.
964 A.J. Ravensberg et al.neutrophils in both sputum18,20 and bronchial tissue,19 and
increased expression of IL-8 in airway epithelium19 in
smokers with asthma. It could be postulated that neutro-
philic inflammation is related to the intensity and duration
of smoking since our smoking asthmatics were younger,
consumed fewer cigarettes and had less pack-years than
the subjects of the above mentioned studies. Indeed, in a
population of asthmatics with similar characteristics to ours
no smoking-related difference in sputum neutrophilia was
detected.6 It has been suggested that young asthmatic
smokers may develop early COPD-like features based on the
observation that they exhibit airway neutrophilia, lung
hyperinflation, lower lung diffusion capacity, increased
baseline airway resistance and emphysematous changes on
HRCT.18 The inflammatory profile we found in our group of
asthmatic smokers may support this concept.
Although both asthma40 and smoking are associated
independently with goblet cell hyperplasia13,14 we did not
detect an increased PAS/ABþ area within the airway
epithelium in smoking asthmatics. Furthermore we found
no difference between the numbers of proliferating Ki67þ
epithelial cells. These results may have been due to a lack
of power since three non-smoking asthmatics whose biopsy
samples showed damaged epithelium only were excluded
from statistical analysis. In fact, increased proliferation of
epithelial cells and goblet cell hyperplasia has been re-
ported in smoking asthmatics compared with non-smoking
asthmatics and was associated with increased epithelial
thickness.21 We did find that the airway epithelium in
smoking asthmatics showed significantly less damage than
that in the non-smoking asthmatics. Since the biopsy sam-
ples from both groups were collected and processed using
identical procedures, it is unlikely that the difference in
epithelial loss between groups is an artifact due to sampling
procedures. Several studies support the hypotheses of
increased epithelial fragility in asthma41e43 and an aberrant
response to epithelial injury in asthma.44e46 Smoking on the
other hand, is associated with increased proliferation of
epithelial cells and wound repair.47,48 It could be specu-
lated that such an adaptive response in smoking asthmaticscould serve as a defence mechanism protecting the airway
epithelium resulting in less injury compared with non-
smoking asthmatics or e in the long term- could result in
aberrant epithelial repair contributing to altered epithelial
function in these patients. Alternatively, increased
epithelial proliferation may be a specific phenotype per se
that facilitates the persistence of smoking in asthma.
Our study shows that smoking induces changes in airway
pathology in asthmatics with a normal lung function at an
early stage, i.e. in those with a limited smoking history
and duration. The inflammatory profile characterized by
increased numbers of CD8þ T lymphocytes and CD68þ
macrophages may be related to the accelerated lung
function decline found in smoking asthmatics and might
may represent early COPD-like changes which could have
consequences for clinical outcomes and asthma treatment
response.10 This underlines the great importance of smok-
ing abstinence and cessation in asthmatics. Thus far,
smoking cessation has been shown to be successful in
improving lung function in asthma.49
In conclusion, our study results indicate that active
smoking in asthma causes a distinct pattern of bronchial
inflammation characterized by infiltration of CD8þ T lym-
phocytes and CD68þ macrophages, and epithelial remod-
elling resembling COPD-like features. Further research is
warranted to investigate whether the early presence of this
particular type of inflammation contributes to disease
progression in smoking asthmatics.
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